Please select the outcome measures that correspond to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.
Brief Summary: The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.


Options:
A: Number of Days of Unscheduled Blood Loss - Cycle 1 (Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)); Number of Days of Unscheduled Blood Loss - Cycle 2 (Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)); Number of Days of Unscheduled Blood Loss - Cycle 3 (Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)); Overall Number of Days of Unscheduled Blood Loss (Cycle 1 to Cycle 3 (Day 8 to Day 80)); Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes (Cycle 1 to Cycle 3 (Day 8 to Day 80)); Number of Days of Scheduled Blood Loss - Cycle 1 (Cycle 1 (Day 22 to 32 for NGM/25mcg EE and day 25 to 32 for DRSP/20mcg EE)); Number of Days of Scheduled Blood Loss - Cycle 2 (Cycle 2 (Day 50 to 60 for NGM/25mcg EE and day 53 to 60 for DRSP/20mcg EE)); Number of Days of Scheduled Blood Loss - Cycle 3 (Cycle 3 (Day 78 to 84 for NGM/25mcg EE and day 81 to 84 for DRSP/20mcg EE)); Overall Number of Days of Scheduled Blood Loss (Cycle 1 to Cycle 3 (Day 8 to Day 84)); Number of Days of Total Blood Loss - Cycle 1 (Cycle 1 (Day 8 to Day 28)); Number of Days of Total Blood Loss - Cycle 2 (Cycle 2 (day 29 to Day 56)); Number of Days of Total Blood Loss - Cycle 3 (Cycle 3 (Day 57 to Day 84)); Overall Number of Days of Total Blood Loss (Cycle 1 to 3 (Day 8 to Day 84)); Number of Participants With Unscheduled Bleeding Cycle 1 (Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)); Number of Participants With Unscheduled Bleeding Cycle 2 (Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)); Number of Participants With Unscheduled Bleeding Cycle 3 (Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)); Number of Participants With Breakthrough Bleeding/Spotting Cycle 1 (Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)); Number of Participants With Breakthrough Bleeding/Spotting Cycle 2 (Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)); Number of Participants With Breakthrough Bleeding/Spotting Cycle 3 (Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE))
B: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms (Efficacy phase was defined as a 90-day period under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7)
C: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms (during a time period of 90 days under treatment)
D: The avoidance of unscheduled surgery in the 28-day follow-up period.; To calculate the time requred from initiation of medical therapy until the cessation bleeding, comparing MPA to monophasic combination oral contraceptive pills.

Answer: B